Array BioPharma (ARRY) Shares are Up 8.02%

Array BioPharma (ARRY) has been under a strong bear grip, hence the stock is down -22.81% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 7.48% in the past 1 week. The stock has risen by 8.02% in the past week indicating that the buyers are active at lower levels, but the stock is down -22.91% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 1.07% and the 50-Day Moving Average is 3.94%.The 200 Day SMA reached 3.04%. Array BioPharma Inc. has dropped 8.85% during the last 3-month period . Year-to-Date the stock performance stands at -17.06%.


Array BioPharma (NASDAQ:ARRY): The stock opened in the green at $3.54 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $3.54 and a low of $3.41 for the day. The stock did not find buyers even at the lows and closed at $3.5 recording a loss of -0.57%. 1,188,483 shares exchanged hands during the trading day. The stock had closed at $3.52 in the previous days trading.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.